Zhang Tiantian, Chen Xudong, Li Caichen, Wen Xiaoqin, Lin Tengfei, Huang Jiaxing, He Jianxing, Zhong Nanshan, Jiang Jie, Liang Wenhua
College of Pharmacy/Guangdong-Hong Kong-Marco Greater Bay Area (GBA), Institue for Real-World Value and Evidence of Drugs and Medical Devices/Southern Institute of Pharmacoeconomics and Health Technology Assessment/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug, Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou 510632, China.
Guangzhou Huabo Biopharmaceutical Research Institute, Guangzhou 510010, China.
Cancers (Basel). 2023 Sep 6;15(18):4445. doi: 10.3390/cancers15184445.
Although the effectiveness of lung cancer screening by low-dose computed tomography (LDCT) could be shown in China, there could be variation in the evidence concerning the economic impact. Our study explores the cost-effectiveness of lung cancer screening and optimizes the best definition of a high-risk population. A Markov model consisting of the natural history and post-diagnosis states was constructed to estimate the costs and quality-adjusted life years (QALYs) of LDCT screening compared with no screening. A total of 36 distinct risk factor-based screening strategies were assessed by incorporating starting ages of 40, 45, 50, 55, 60 and 65 years, stopping ages of 69, 74 and 79 years as well as smoking eligibility criteria. Screening data came from community-based mass screening with LDCT for lung cancer in Guangzhou. Compared with no screening, all screening scenarios led to incremental costs and QALYs. When the willingness-to-pay (WTP) threshold was USD37,653, three times the gross domestic product (GDP) per capita in China, six of nine strategies on the efficiency frontier may be cost-effective. Annual screening between 55 and 79 years of age for those who smoked more than 20 pack-years, which yielded an incremental cost-effectiveness ratio (ICER) of USD35,000.00 per QALY gained, was considered optimal. In sensitivity analyses, the result was stable in most cases. The trends of the results are roughly the same in scenario analyses. According to the WTP threshold of different regions, the optimal screening strategies were annual screening for those who smoked more than 20 pack-years, between 50 and 79 years of age in Zhejiang province, 55-79 years in Guangdong province and 65-74 years in Yunnan province. However, annual screening was unlikely to be cost-effective in Heilongjiang province under our modelling assumptions, indicating that tailored screening policies should be made regionally according to the local epidemiological and economic situation.
尽管低剂量计算机断层扫描(LDCT)肺癌筛查的有效性在中国已得到证实,但关于其经济影响的证据可能存在差异。我们的研究探讨了肺癌筛查的成本效益,并优化了高危人群的最佳定义。构建了一个由自然病史和诊断后状态组成的马尔可夫模型,以估计与不进行筛查相比,LDCT筛查的成本和质量调整生命年(QALY)。通过纳入40、45、50、55、60和65岁的起始年龄、69、74和79岁的停止年龄以及吸烟资格标准,共评估了36种基于不同风险因素的筛查策略。筛查数据来自广州社区基于LDCT的肺癌大规模筛查。与不进行筛查相比,所有筛查方案都会导致成本增加和QALY增加。当支付意愿(WTP)阈值为37,653美元(中国人均国内生产总值的三倍)时,效率前沿上的九种策略中有六种可能具有成本效益。对于吸烟超过20包年的人群,在55至79岁之间进行年度筛查,每获得一个QALY的增量成本效益比(ICER)为35,000.00美元,被认为是最佳方案。在敏感性分析中,大多数情况下结果是稳定的。情景分析中结果趋势大致相同。根据不同地区的WTP阈值,浙江省的最佳筛查策略是对吸烟超过20包年的人群在50至79岁之间进行年度筛查,广东省为55至79岁,云南省为65至74岁。然而,在我们的建模假设下,黑龙江省年度筛查不太可能具有成本效益,这表明应根据当地的流行病学和经济情况制定因地制宜的筛查政策。